Genmab's petosemtamab plus pembrolizumab halves risk of death in Phase 3 head and neck cancer trial
At the first interim analysis of LiGeR-HN1 the overall survival hazard ratio was 0.50; medians and full data were not disclosed.
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
- Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- FDA grants accelerated approval to Inovio's Voceryq, the first US plasmid DNA immunotherapy, for adult RRP
- Anthropic renames Claude Max 20x to Ultra and drops the 5-hour limit for verified Ultra accounts
- OpenAI reorganizes its Model Spec around five core values